Sign in

CIK 0001819411

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Gain Therapeutics, Inc.

Sign in to watch
Ticker
GANX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
851726310
Phone
+1 301-500-1556
Business address
4800 HAMPDEN LANE, SUITE 200, BETHESDA, MD, 20814
  1. 4 Open-market buy CFO and Interim CEO bought 14,400 shares at $1.01 ($14,544)
  2. 4 Open-market buy Executive Chairman bought 50,000 shares at $1.00 ($49,940)
  3. 4 Open-market buy Director bought 17,000 shares at an average $1.22 ($20,670)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 4 Open-market buy Director bought 30,000 shares at $3.86 ($115,770)
  14. 4 Shares withheld for taxes Chief Executive Officer gave up 6,085 shares (to pay taxes)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Open-market sale Chief Executive Officer sold 206 shares at $2.46 ($507)
  18. 4 Open-market sale Chief Executive Officer sold 1,820 shares at $2.50 ($4,550)
  19. 4 Option exercise Chief Executive Officer acquired 825 shares (option exercise)
  20. 4 Option exercise Director acquired 54,900 shares (option exercise)

Page 2 of 5 · 82 filings